Open Access
Review Article
September-October 2026, Vol. 02 (5), 27-44
International Journal of Pharmaceutical
Research and Medicinal Plants
(An International Peer Reviewed Journal)
Phytochemical Nanocarriers: Translating Traditional Botanical
Therapeutics into Modern Nanomedicine
Abhishek Tripathi*
and Harroshandeep Kaur Phull
University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab 140413, India
ARTICLE INFO:
ABSTRACT
Received:
26
th
Sept.
2026
;
Received
in
revised form: 03
rd
Oct. 2026
;
Accepted:
10
th
Oct.
2026
;
Available
online:
30
th
Oct. 2026.
Keywords:
Phytochemicals,
Nanomedicine, Herbal medicine,
Nanocarriers, Phytosomes,
Bioavailability, Targeted delivery,
Quality by design.
DOI:
https://doi.org/10.61280/5000mf06
*Corresponding
Author:
Abhishek
Tripathi
Email:
25ypd50008@cuchd.in
Natural
products
are
a
rich
source
of
drug-like
phytochemicals;
however,
the
clinical
success
of
promising
candidates
has
been
hampered by issues such as insolubility, instability, rapid metabolism,
limited
tissue
distribution,
and
variation.
Systems
designed
for
drug
delivery can tackle such problems by improving dispersion, protecting
labile phytochemicals from degradation, customizing release kinetics,
and
changing
membrane
interactions.
We
review
lipid
carriers,
liposomes, phytosomes, solid lipid nanoparticles, nanostructured lipid
carriers,
polymeric
nanoparticles,
nanoemulsions,
micelles,
nanocrystals,
proteinaceous
nanoparticles,
and
some
hybrid
systems
for the delivery of phytopharmaceuticals. The original article searches
PubMed/MEDLINE,
ScienceDirect,
Scopus-indexed
articles,
and
Google
Scholar.
None
of
the
search
archives
were
exported
for
verification;
thus,
there
is
no
documented
date
for
the
last
search
undertaken,
no
deduplication
report,
no
documentation
of
screening
by
an
independent
reviewer,
and
the
PRISMA
diagram
numbers
cannot be verified. The unverified number of studies are not presented
as systematic-review results in this updated article for these reasons.
This
review
holds
the
most
studied
phytochemicals
of
curcumin,
resveratrol,
quercetin,
berberine,
epigallocatechin
gallate,
and
silymarin, as the limitations to their delivery have been most clearly
defined
here.
Many
formulation
studies
show
enhancement
of
properties such as perceived solubility, stability, release properties, or
pharmacokinetic
parameters;
however,
they
are
very
dependent
on
formulation, dose, route, model, and comparison. Better delivery does
not
automatically
demonstrate
clinical
effectiveness.
There
is
insufficient
pharmacokinetic
profile
data,
incomplete
quality
attributes,
scale-up
issues
or
challenges,
carrier
toxicity,
and
fewer
well-controlled
clinical
studies.
Our
product-by-product
solution
encompasses
botanical
verification,
chemical
fingerprinting,
quality-
by-design
formulation,
orthogonal
characterization,
case-specific
safety
evaluation,
and
controlled
clinical
testing
when
proper.
Nanocarriers play a prominent role in the development of botanical
Copyright:
©
Author
2026
by
the
Author.
International
Journal
of
Pharmaceutical
Research
and
Medicinal
Plants
Published
by
Informative Journals
(Jadoun Science Publishing Group India). This article is an open access article distributed under the terms and conditions
of the CC BY-NC-ND 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 27
medicines;
however,
they
are
NOT
considered
a
basis
for
efficacy
claims in and of themselves. Thus, the conclusions that may be drawn
from the assessment of a drug delivery system should be equal with
the level of quality and maturity of the data available.
1. INTRODUCTION
Medicinal
plants
have
informed
health
practices
in
Ayurveda,
Traditional
Chinese
Medicine,
Unani,
and
Indigenous
systems,
and
are
an
important
source
of
pharmacologically
active
molecules.
Contemporary
phytopharmacology
seeks
to
identify
the
active
constituents,
understand
the
mechanisms,
and
establish
reproducible dosage forms. Botanical preparations are chemically complex; activity can arise from a single
molecule,
multiple
constituents,
metabolites,
or
interactions
between
constituents.
This
complexity
is
valuable but makes dose definition, quality control, and the interpretation of clinical outcomes challenging
[1-8]. Many phytochemicals face delivery barriers. Hydrophobic compounds, such as curcumin, resveratrol,
and
quercetin,
have
limited
aqueous
solubility;
some
are
unstable
under
light,
oxygen,
pH,
or
enzymatic
exposure, and rapid conjugation or efflux may limit systemic exposure. Highly polar constituents may not
cross lipid membranes. A conventional extract may vary with species identity, cultivar, geography, harvest,
storage, extraction solvent, and processing [9-16].
Nanomedicine
provides
formulation
approaches
that
can
protect
compounds,
improve
dispersion,
alter
release, and interact with barriers. The carrier itself does not confer pharmacological activity; it changes the
exposure profile and may introduce new risks. The question is not whether a nanoformulation is smaller, but
whether
a
defined
formulation
offers
a
meaningful,
reproducible,
and
safe
improvement
on
a
suitable
comparator [17-24]. This review connects traditional botanical medicines with modern carrier engineering.
Carrier classes are evaluated, phytochemical
examples are discussed, along with analytical and biological
evidence,
clinical
translation,
safety,
and
regulatory
needs.
Findings
are
described
according
to
evidence
level, and preclinical signals are not treated as human efficacy.
2. REVIEW OBJECTIVES AND QUESTIONS
This
review
aimed
to
respond
to
the
following
questions:
(i)
what
carrier
systems
are
used
for
phytochemicals;
(ii)
what
formulation
mechanisms
can
enhance
stability,
absorption,
and
targeting
properties;
(iii)
which
compounds
and
therapeutic
areas
are
considered
the
most
promising;
(iv)
what
preclinical and clinical evidence can support the translation from in vitro and animal studies; and (v) what
quality, safety, and regulatory issues need to be addressed before clinical applications.
3. MATERIALS AND METHODS
3.1 Review design
This
article
was
designed
as
a
critical
narrative
review
with
a
structured
approach
to
literature
identification
and
synthesis
.
Its
purpose
was
to
examine
phytochemical
nanocarrier
technologies,
representative bioactive compounds, reported formulation outcomes, and barriers to clinical translation. The
review does not claim to be a systematic review or meta-analysis because a complete reproducibility record
was not available, including final database search histories, exported records, deduplication files, screening
decisions, and study-level extraction sheets. Accordingly, the findings are presented as a structured critical
synthesis
rather
than
as
a
quantitative
estimate
of
the
literature.
The
review
focuses
on
the
strength
and
limitations
of
the
available
evidence
and
distinguishes
physicochemical,
in
vitro,
animal,
and
human
findings. It does not treat improvements in formulation characteristics or preclinical outcomes as evidence of
clinical effectiveness.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 28
3.2 Information sources and search concepts
The initial literature search drew on PubMed/MEDLINE, ScienceDirect, Scopus-indexed publications, and
Google
Scholar.
Reference-list
screening
and
searches
of
authoritative
regulatory
or
guidance
documents
were used to show added relevant material.
Search
concepts
combined
terms
for
phytochemicals
and
botanical
medicines
with
terms
for
nanocarrier-
based delivery systems. Phytochemical and botanical terms included
phytochemicals
,
plant extract
,
herbal
medicine
,
curcumin
,
resveratrol
,
quercetin
,
berberine
,
silymarin
, and
epigallocatechin gallate
. These terms
were combined with delivery-related terms, including
nanocarriers
,
nanoparticles
,
liposomes
,
phytosomes
,
nanoemulsions
,
solid lipid nanoparticles
,
nanostructured lipid carriers
,
polymeric nanoparticles
,
micelles
,
nanocrystals
,
vesicles
,
targeting
, and
bioavailability
.
Because the exact database-specific search strings and final search dates from the first work were not kept,
this review does not present the search process as fully reproducible or exhaustive. The literature was used to
show recurring
carrier strategies, representative phytochemicals, commonly reported outcomes, and major
translational limitations.
3.3 Scope and eligibility of the literature considered
The synthesis considered peer-reviewed original research, review articles used for contextual background and
citation
tracking,
human
clinical
studies,
and
official
guidance
relevant
to
nanomaterial-containing
medicines. Priority was
given to
literature
addressing plant-derived bioactives and nanocarrier systems
in
relation
to
formulation
characteristics,
stability,
release,
absorption,
pharmacokinetics,
biodistribution,
biological
activity,
safety,
manufacturing,
or
clinical
translation.
Studies
focused
exclusively
on
synthetic
drugs
or
non-medicinal
materials
were
not
central
to
the
review
unless
they
provided
directly
relevant
information on carrier design, characterization, safety assessment, or regulatory considerations applicable to
phytochemical formulations. Review articles were used to contextualize the field and find relevant primary
studies; they were not treated as independent experimental evidence.
3.4 Evidence organization and critical synthesis
The literature was organized according to carrier architecture, phytochemical class, therapeutic application,
and stage of evidence. Evidence was categorized as physicochemical, in vitro, animal, human, or marketed-
product
evidence
where
applicable.
The
synthesis
considered
botanical
or
compound
identity,
carrier
composition,
particle size, and disparity when reported, encapsulation or loading, route of administration,
comparator, biological
outcome, safety
information, and stated limitations. Given the marked diversity
of
carrier systems, active compounds, study models, routes of administration, doses, analytical methods, and
outcome
measures,
a
pooled
quantitative
analysis
was
not
proper.
Instead,
the
review
critically
examines
whether reported formulation advantages are supported by suitable comparators and whether they provide a
plausible basis for later translational development.
3.5 Interpretation of evidence and methodological limitations
The review applies an evidence-level framework to avoid equating laboratory or animal findings with clinical
benefit. Improvements in particle size, encapsulation efficiency, stability, release behaviour, cellular uptake,
or
pharmacokinetic
exposure
are
interpreted
as
formulation-related
findings.
Such
outcomes
may
support
further development but do not independently prove therapeutic superiority, safety, or clinical efficacy. The
review has several limitations. A fully reproducible systematic-review process would require a dated search
update,
database-specific
search
strings,
exported
records,
documented
deduplication
procedures,
independent
title-and-abstract
and
full-text
screening,
reasons
for
exclusion,
and
a
PRISMA
2020
flow
diagram based on an auditable screening record. Study-level risk-of-bias assessment would also be needed,
using design-appropriate tools such as RoB 2 for randomized clinical trials and SYRCLE for animal studies.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 29
Because these materials were not available for the present review, the findings should be interpreted as a
critical narrative appraisal of the field rather than as a systematic estimate of the evidence base.
4. RESULTS
4.1 Overview of the evidence landscape
In the evidence configuration described many of the considered manuscripts are focused on formulations and
preclinical
findings.
Indeed,
the
triple
combination
of
curcumin,
resveratrol
and
quercetin
is
mentioned
several
times
due
to
its
reported
insufficient
aqueous
solubility,
chemical
instability,
or
rapid
metabolic
transformation. Berberine, epigallocatechin gallate, silymarin and other phytochemicals are also mentioned in
the
context
of
different
carriers.
In
this
regard,
encapsulation
is
proposed
to
improve
the
content
of
the
entrapped substance, decrease its degradation rate, change the release properties, or enhance the exposure of
the target tissue. These are several aspects, and the cumulative evidence grade should not be confused by the
presence of any single positive result. A higher encapsulation efficiency, reduced particle size, or increased in
vitro efficacy message cannot be used as sufficient proof of a compound’s superiority.
One of the key conclusions of this evidence synthesis is that the number of studies with potentially valuable
formulations significantly exceeds the quantity of positive clinical findings. Preclinical and physicochemical
data are represented by a substantial number of articles, while human evidence is mostly ranked as moderate
or low due to the absence of consistent control groups. Animal studies are even more challenging to analyze
due
to
the
wide
range
of
interventions
and
study
designs
used
in
different
research
groups.
Therefore,
comparative efficacy claims are mostly based on head-to-head trials, which directly compare the same test
substance
or
combination.
Indeed,
comparing
the
same
dose
of
the
entrapped
compound,
the
free
drug
formulation
(if
applicable)
and
carrier-alone
is
the
optimal
strategy
to
prove
the
value
of
a
new
delivery
system.
For
pharmacokinetic
claims,
the
use
of
validated
and
consistent
analytical
techniques
is
critical,
while the inclusion of clinically relevant efficacy endpoints requires researchers to design a suitable control
group. At the same time, the current state of the analyzed body of evidence does not allow for conducting
large-scale quantitative analysis or producing a single grade for individual carriers. This is due to the lack of
access to individual participant data and the completion of the risk of bias assessment by the original authors.
Table 1:
Evidence domains used to compare phytochemical carrier studies.
|
Evidence domain
|
Common reported endpoint
|
Interpretive caution
|
|
Physicochemical
|
Particle
size,
PDI,
zeta
potential,
loading,
encapsulation efficiency
|
Values
depend
on
method,
medium,
dilution,
and
storage;
a
single
size
value
is
insufficient.
|
|
In vitro delivery
|
Dissolution,
release,
cell
uptake,
cytotoxicity,
antioxidant assays
|
Assay
interference
and
non-
physiological
concentrations
can exaggerate these effects.
|
|
Animal studies
|
AUC/Cmax, tissue distribution,
disease scores, histology
|
Species,
routes,
model,
and
dose
may
not
predict
human
benefit.
|
|
Human studies
|
Pharmacokinetics,
tolerability,
symptoms, biomarkers, clinical
endpoints
|
Small
sample
sizes
and
surrogate
outcomes
may
not
show effectiveness.
|
The table summarizes commonly reported endpoints and the main cautions needed for interpretation; it is a
framework for synthesis rather than a claim that every study reported every endpoint.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 30
4.2 Major nanocarrier systems
4.2.1 Liposomes and related vesicles
Liposomes are phospholipid membranes that can encapsulate hydrophilic molecules in their aqueous cores
and hydrophobic ones in the membrane itself. They can be made from various phospholipids, cholesterol,
PEG, ligands, and other materials depending on the desired properties. Phytochemicals can be enclosed in
liposomes to target certain tissues and provide therapeutic benefits. Their advantages include protection of
the payload and altered biodistribution, while the challenges are leakage, lipid auto-oxidation or hydrolysis,
stability, and cost [49–58].
Niosomes,
transfersomes,
and
ethosomes
are
like
liposomes
but
have
several
types
of
surfactants
or
can
deform
under
pressure.
Transfersomes
and
ethosomes
are
particularly
interesting
for
the
enhanced
penetration
of
their
contents
into
the
skin
layers.
However,
such
data
require
other
validation
through
permeation studies, as well as evaluation of irritation and systemic exposure if applicable [59–64].
4.2.2 Phytosomes and phospholipid complexes
Phytosomes
can
be
described
as
association
products
of
plant-derived
material
and
phospholipids,
not
aqueous-core liposomes. The involvement of hydrogen bonding and other interactions may contribute to their
enhanced
partitioning
and
absorption
of
specific
polyphenols
such
as
curcumin,
silybin
or
grape-seed
polyphenols.
Available
phytosomal
products
on
the
market
cannot
prove
their
similarity
in
terms
of
the
content of botanical ingredients or ratio of ligand/phospholipid, technological aspects, and clinical data [65–
72].
4.2.3 Solid lipid nanoparticles and nanostructured lipid carriers
Solid lipid
nanoparticles (SLNs) are
formed from
a solid lipid
matrix, while nanostructured lipid
carriers
(NLCs) are composed of solid and liquid lipids, allowing the formation of a less ordered matrix having a
higher amount of active compound and reducing its expulsion during storage. The use of SLNs and NLCs for
the
delivery
of
lipophilic
phytochemicals
can
provide
protection
to
the
active
compounds
and
can
be
developed
in
oral,
topical
or
parenteral
formulations.
However,
the
potential
limitations
include
drug
expulsion due to crystal growth, polymorphic transformations, tolerability of surfactants used, lipid digestion
and variable release rates in biological fluids [73–80].
4.2.4 Polymeric nanoparticles and nanocapsules
Polymeric carriers can be made from biodegradable polymers, such as poly (lactic-co-glycolic acid) (PLGA),
polylactide, chitosan, alginate, gelatin, or other natural and synthetic polymers. Nanocapsules can generate a
reservoir-type structure, while nanospheres have the active principle dispersed within the polymer matrix.
Properties of surface chemistry, polymer molecular weight, degradation rate, and residual solvent should be
considered. The fact that the polymer is biodegradable is not dispensable for the comprehensive evaluation of
the
product
and
its
toxicity;
thus,
characterization
of
degradation
products,
immunological
response
and
repeated-dose toxicity studies are needed [81-90].
4.2.5 Nanoemulsions, micelles and nanocrystals
Nanoemulsions are kinetically stable dispersions of oil in water stabilized by surfactants; they may enhance
the plain solubilization and gastrointestinal dispersion of hydrophobic constituents. Micelles can solubilize
hydrophobic molecules
within hydrophobic domains
and may be useful
when the unperturbed compound
precipitates
out
of
aqueous
media.
Nanocrystals
increase
the
surface
area
and
thus
the
dissolution
rate
without
requiring
a
large
carrier
mass.
The
technologies
are
not
interchangeable:
a
nanoemulsion
is
not
necessarily thermodynamically stable, and increased dissolution does not always lead to increased absorption
[91–99].
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 31
4.2.6 Protein-based, polysaccharide and hybrid systems
Albumin,
casein,
zein,
gelatin
and
other
food-compatible
proteins
can
interact
with
plant
bioactives
via
hydrophobic
interactions,
hydrogen
bonding,
or
electrostatic
forces.
Polysaccharides
such
as
chitosan,
alginate
and
pectin
can
provide
mucoadhesion,
pH
sensitivity
or
protective
matrices.
Hybrid
systems
are
combinations of materials to tailor loading, stability, or triggered release. Their performance is influenced by
ionic strength, digestive enzymes, protein corona formation, presence of food components and batch-to-batch
variations in materials [100–108].
4.2.7 Inorganic, metallic, and biomimetic systems
Gold, silver, silica, iron oxide, and other inorganic nanomaterials have been explored as carriers, imaging
agents, or components of multifunctional systems. Their long persistence, surface reactivity and potential for
accumulation make them different from many biodegradable organic carriers. Green synthesis using plant
extracts
may
provide
reducing
or
capping
molecules,
but
plant-mediated
synthesis
is
not
guaranteed
to
produce reproducible, pure, or safe materials. Exosomes and cell-membrane-inspired systems are promising
carriers,
but
require
careful
characterization
of
sources,
scalable
isolation
methods,
and
control
of
the
biological cargo [109–116].
Table 2:
Comparison of major carrier platforms used for phytochemical delivery.
|
Carrier class
|
Potential advantage
|
Key limitations/tests
|
|
Liposomes/vesicles
|
Encapsulate
polar
and
nonpolar
compounds; modifiable surface
|
Leakage,
oxidation,
storage
stability, sterilization and scale-up
|
|
Phytosomes
|
Phospholipid
complex
may
improve
partitioning
and
absorption
|
Must
confirm
complex
formation,
composition,
and
product-specific
clinical evidence
|
|
SLN / NLC
|
Lipid
compatibility;
protect
lipophilic actives
|
Polymorphism,
drug
expulsion,
digestion, and surfactant effects
|
|
Polymeric nanoparticles
|
Tunable
degradation
and
release;
surface
functionalization
|
Residual
solvent,
polymer
impurities, degradation, and repeat-
dose toxicity
|
|
Nanoemulsions/micelles
|
Improve
dispersion
and
clear
solubilization
|
Dilution/food effects, precipitation,
surfactant burden, and stability
|
|
Protein/polysaccharide
|
Biocompatible
matrices;
mucoadhesion or pH response
|
Batch
variability,
digestion,
allergenicity, and ionic sensitivity
|
|
Inorganic / hybrid
|
Imaging,
external
responsiveness,
multifunctionality
|
Persistence,
biodistribution,
clearance,
and
long-term
toxicology
|
Carrier
selection
should
be
guided
by
the
compound’s
chemistry,
route,
target
tissue,
manufacturing
constraints, and safety profile rather than particle size alone [17, 23, 49, 65, 73, 81, 91, 100, 109].
4.3 Representative phytochemicals and formulation rationale
4.3.1 Curcumin
Curcumin,
an
active
part
of
Curcuma
longa,
has
been
subject
to
extensive
investigation
for
its
anti-
inflammatory and antioxidant activity. However, the low aqueous solubility, chemical
stability, and rapid
metabolism
limit
the
oral
bioavailability.
Various
nanoparticle
systems
such
as
liposomes,
polymeric
nanoparticles, lipid-based carriers, micelles, nanocrystals, and phytosomes have been explored to improve the
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 32
delivery of curcumin. A systematic review of the literature focusing on the nanoparticle delivery of curcumin
highlighted the need to differentiate between the enhancement of pharmacokinetic properties and antitumor
efficacy
and
to
compare
the
performance
of
different
formulations
[117–121].
In
addition,
curcumin-
containing formulations require a chemical characterization of curcuminoids and their degradation products,
and
only
formulations
that
have
proven
efficacy
in
a
controlled
clinical
study
of
humans
can
make
pharmacological claims.
4.3.2 Resveratrol
Resveratrol,
a
stilbenoid
found
in
grapes
and
several
other
plant
species,
has
poor
aqueous
solubility,
undergoes
photoisomerization,
oxidation,
and
rapid
metabolic
conversion.
Encapsulation
in
liposomes,
polymeric
nanoparticles,
lipid
nanocarriers,
micelles,
nanoemulsions,
and
protein
carriers
have
been
investigated.
Recent
reviews
highlight
the
importance
of
optimizing
formulations
to
improve
pharmacokinetic parameters and underscore the need for further investigations of the therapeutic potential
and safety of resveratrol in vivo [122–126].
4.3.3 Quercetin and other flavonoids
Quercetin is associated with low aqueous solubility and undergoes extensive metabolism. Thus, lipid-based
formulations, polymeric systems, cyclodextrin complexes, micelles, and nanoemulsions have been explored
for
the
delivery
of
this
flavonoid.
Similarly,
other
flavonoids
including
EGCG,
naringenin,
genistein,
kaempferol,
and
fisetin
have
been
studied;
each
exhibits
different
stability
and
metabolic
profiles,
and
therefore, a flavonoid delivery platform cannot be extrapolated from one compound to another [127–132].
4.3.4 Berberine, silymarin and other botanical actives
Berberine is an isoquinoline alkaloid that is subject to limited oral bioavailability due to its poor absorption
and extensive metabolism and/or excretion processes. Thus, nanocarriers reviewed by the authors of [129]
are
lipids,
polymeric
particles,
and
other
systems
designed
to
improve
the
pharmacokinetics
and
tissue
distribution of the drug. At the same time, the study [129] notes that silymarin/silybin, artemisinin, celastrol,
boswellic acids, andrographolide, and other phytochemicals have also been used to deliver various natural
products. However, each of these compounds requires a detailed description of the chemical markers and a
thorough assessment of interactions and safety data; thus, an isolated molecule of a drug is not identical to a
complex of a natural product [133–138].
Table 3:
Commonly investigated phytochemicals and their formulation rationale.
|
Phytochemical
|
Botanical source
(example)
|
Main formulation
challenge
|
Platforms explored
|
|
Curcumin
|
Curcuma longa
|
Poor aqueous solubility;
rapid metabolism
|
Phytosomes, liposomes,
polymeric and lipid
nanoparticles
|
|
Resveratrol
|
Vitis vinifera and others
|
Solubility,
photoisomerization,
oxidation
|
Liposomes, micelles,
lipid/polymeric particles
|
|
Quercetin
|
Many fruits and
medicinal plants
|
Low solubility;
extensive metabolism
|
Lipid carriers, polymeric
systems, cyclodextrins
|
|
Berberine
|
Berberis spp., Coptis
spp.
|
Low systemic exposure;
transporter/metabolic
effects
|
Polymeric and lipid-based
nanocarriers
|
|
EGCG
|
Camellia sinensis
|
Chemical instability and
limited exposure
|
Liposomes, polymeric
and protein-based carriers
|
|
Silybin
|
Silybum marianum
|
Low solubility and
variable absorption
|
Phytosomes, lipid
carriers, nanoparticles
|
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 33
These examples reflect research directions and do not imply equivalent clinical evidence across products or
indications [65–72, 117–138].
4.4 Mechanisms by which carriers may alter delivery
One
of
the
basic
characteristics
of
delivery
carriers
is
the
ability
to
prove
activity
through
their
action,
regardless of the mechanism of action. The mechanism of action of the carrier can differ and include: (i)
enhancement
of
wetting
and
dispersion;
(ii)
protection
of
the
compound
from
hydrolysis,
oxidation,
photolysis
or
metabolic
transformations;
(iii)
regulation
of
the
dissolution
profile;
(iv)
promotion
of
penetration
through
barriers
(epithelial
or
cellular);
(v)
modulation
of
lymphatic
absorption
or
the
reticuloendothelial
system;
(vi)
targeting
of
specific
sites
by
virtue
of
a
ligand,
local
administration,
or
response to a stimulus. In addition to the examples listed, the ability of a carrier to direct the drug to the site
of action varies depending on the formulation and route of administration, and this must be considered when
designing
the
system,
not
taken
for
granted
[139–142].
Such
factors
as
surface
charge,
particle
size
distribution,
shape,
rigidity,
protein
binding,
and
interaction
with
mucin
also
affect
the
properties
of
the
carrier. One should be especially careful about the common assertion that nanoparticles are delivered to the
tumour
via
the
enhanced
permeability
and
retention
effect.
Vascular
permeability
in
humans
is
heterogeneous,
and
nanoparticle
accumulation
in
tumour
tissue
in
preclinical
studies
does
not
always
translate into clinical success. Targeting using targeting ligands can increase cellular uptake but has slight
effect on overall tissue distribution [20–24, 143–147].
Figure 1:
Product-specific development pathway for nano-phytomedicine
Figure 1 The pathway links botanical authentication and chemical fingerprinting with formulation, quality,
and safety testing, and clinical validation. Each stage is a decision gate requiring product-specific evidence;
progression through the pathway should not be assumed.
5. DISCUSSION
The
evidence
supports
nanocarriers
as
enabling
pharmaceutical
technologies
for
selected
phytochemicals
when a defined physicochemical barrier is overcome by a compatible formulation (e.g., improved dissolution
or prevention of degradation). The most convincing arguments begin with a mechanistic problem (such as
poor dissolution or rapid degradation) and show how the exposure variable (relevant to the mechanism) is
changed by the carrier and shows a biological effect at a comparable or clinically relevant dose. Novelty by
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 34
itself is not an outcome. A recurring weakness is an overreliance on in vitro assays and on a single animal
model. Cell-based antioxidants or cytotoxicity assays can give misleading results if the nanoparticle causes
light scattering, fluorescence quenching or adsorption of assay reagents
or non-specific membrane injury.
Blank-carrier
controls,
orthogonal
assays,
and proper analysis of the dose-response
are needed.
Improved
plasma concentrations in animals must be related to unbound concentration at the target site and linked to a
relevant pharmacodynamic endpoint. Positives and negatives should be reported.
Botanical
quality
is
a
fundamental
issue.
Correct
species
identification,
plant
part,
extraction
method,
chromatographic fingerprint, marker compound ranges, contaminants, and stability must be defined before
carrier optimization. A nano formulation may increase exposure not only of desired constituents but also of
contaminants or unwanted constituents. Whole extract delivery raises questions of whether the active cocktail
is stable during manufacturing and storage and whether the carrier preferentially partitions some constituents
and
thereby
changes
the
original
phytochemical
profile
[1–8,65–72].
The
carrier
itself
can
carry
risks.
Cationic surfaces can damage membranes, surfactants can be irritating or disrupt barrier integrity, inorganic
components
can
be
kept
in
tissue
and
polymers,
or
lipids
can
change
degradation
profiles,
immune
recognition, or biodistribution. The safety profile of the free phytochemical cannot be relied on as a surrogate
for
the
final
formulation.
Appropriate
evaluation
would
include
route-relevant
local
tolerance,
systemic
toxicity,
immunogenicity
where
relevant,
reproductive
or
genotoxicity
when
indicated
and
potential
interactions in the relevant population.
Clinical
translation
is
still
the
outstanding
challenge.
Some
phytosomal
and
enhanced-bioavailability
botanical products are available; selected formulation-specific clinical studies are available; nevertheless, a
commercial
label,
small
trial
or
surrogate
biomarker
does
not
constitute
broad
therapeutic
effectiveness.
Human studies should use rigorous randomization, sufficient sample size, pre-specified outcomes, validated
analytical assays, dose justification, clinically relevant comparator, and systematic adverse event reporting. A
conventional
extract
and
nano
formulation
should
be
compared
directly
if
nanotechnology
is
claimed
to
enhance clinical benefit. The next generation of research should focus on quality-by-design, critical quality
attributes, robust scale-up, continuous manufacturing where proper, stability-indicating analytical methods,
realistic
biorelevant
testing,
physiologically
based
pharmacokinetic
modelling
and
early
regulatory
engagement.
AI
and
computational
screening
may
aid
in
prioritizing
carrier
compositions;
however,
predictions
will
need
experimental
verification.
Sustainable
sourcing
and
reduced
solvent
use
are
also
important if a technology to enhance plant-derived medicine is to avoid creating an avoidable environmental
burden.
5.1 Translational evidence and decision points
Table 4:
Suggested stage-gate framework for translating nano-phytomedicines.
|
Development stage
|
Minimum evidence package
|
Decision question
|
|
Botanical / compound
definition
|
Taxonomic authentication,
fingerprint, marker assay,
contaminants, stability
|
Is the active material
reproducible and adequately
defined?
|
|
Formulation optimization
|
Size distribution, morphology,
loading, release, residuals,
batch variation
|
Does the carrier solve a defined
limitation?
|
|
Preclinical proof
|
Relevant controls, exposure
measurements, efficacy model,
route-specific toxicology
|
Does improved delivery
produce a meaningful benefit at
tolerable exposure?
|
|
Clinical translation
|
Human pharmacokinetics, dose
|
Is the specific product better
|
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 35
|
finding, randomized efficacy
trial, safety monitoring
|
than a suitable comparator?
|
|
Manufacturing/lifecycle
|
Validated process,
specifications, stability, change
control, pharmacovigilance
|
Can quality and safety be
supported on a scale?
|
Each stage should be passed using product-specific data; evidence from another compound or carrier cannot
substitute for validation of the candidate formulation [23, 40–48, 148–152].
5.2 Limitations of this review
Several
limitations
affect
interpretation.
The
manuscript
brings
together
a
mix
of
compounds,
carrier
compositions,
routes,
models,
and
outcomes,
which
prevents
a
defensible
quantitative
synthesis
without
defining
a
narrower
question
and
harmonizing
the
data.
The
provided
source
did
not
include
archives
of
search histories, a verified search cutoff, deduplication and screening logs, reasons for full-text exclusion, a
complete PRISMA count record or completed study-level risk-of-bias assessments. Therefore, the revised
manuscript enhances structure and transparency but cannot honestly claim that these reproducibility steps
have
been
completed.
Publication
bias
and
selective
reporting
could
enhance
positive
findings
on
formulation,
while
incomplete
characterizations
make
cross-study
comparisons
unreliable.
Before
submission, a subject librarian or experienced co-author should reproduce the searches independently, verify
eligibility
decisions,
check
the
extracted
data
against
original
reports,
and
confirm
each
risk-of-bias
judgement.
Figure 2:
Overview of carrier classes investigated for phytochemical delivery.
Figure
2
Representative
carrier
families
include
liposomes,
phytosomes,
lipid
nanoparticles,
polymeric
particles, nanoemulsions or micelles, and protein-based or hybrid systems. The diagram is conceptual and
does not imply that one platform is universally superior.
6. FUTURE PERSPECTIVES
Future
development
should
be
focused
on
clinically
relevant
rather
than
purely
technological
advances,
including oral carriers that are resistant to digestion and deliver their payloads at a desired site within the
intestine, topical carriers with characterized skin deposition and tolerability, inhalation or parenteral systems
with
strict
control
over
sterility,
endotoxin
and
biodistribution,
or
disease-targeted
platforms
with
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 36
reproducible target engagement. Combination delivery of multiple phytochemicals may be a useful strategy,
but it increases the burden of characterizing the components and their interactions.
A pragmatic translation strategy would be to choose a small number of well-characterized phytochemicals
with an established exposure limitation, use a carrier with a compelling safety and manufacturing rationale
and
analytical
comparability
between
batches,
and
continue
through
pharmacokinetic
and
dose-ranging
investigations. Traditional medicines may guide compound
choice and therapeutic domain,
while modern
chemistry, pharmacology, and clinical science define identity, quality, safety, and efficacy.
7. CONCLUSION
Novel carrier systems stand for a viable link between traditional botanical medicine and nanomedicine by
addressing selected delivery limitations and challenges that phytochemicals face. Liposomes, phytosomes,
lipid
and
polymeric
nanoparticles,
nanoemulsions,
micelles
and
other
systems
can
help
to
improve
dispersion,
protect
unstable
compounds,
alter
release
and,
in
some
cases,
boost
exposure
or
biological
activity. The extent and importance of these benefits are compound-, carrier-, route- and product-specific.
Preclinical improvements should not be extrapolated to proof of efficacy in humans, and carrier-related risks
need
to
be
assessed
independently
of
the
botanical
ingredient.
Advancement
requires
botanical
authentication, chemical fingerprinting, thorough characterization, reproducible manufacturing, appropriate
toxicology,
rigorous
human
studies,
and
transparent
regulatory
evaluation.
The
field
will
realize
its
true
potential when nanotechnology is used to solve a defined delivery problem and when every claim is backed
up by evidence for the final formulation.
REFERENCES
-
1.
World Health Organization. WHO traditional medicine strategy: 2014–2023. Geneva: WHO; 2013.
-
2.
Atanasov
AG,
Waltenberger
B,
Pferschy-Wenzig
EM,
et
al.
Discovery
and
resupply
of
pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-
1614. doi:10.1016/j.biotechadv.2015.08.001.
-
3.
Newman
DJ,
Cragg
GM.
Natural
products
as
sources
of
new
drugs
over
the
four
decades
from
01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285.
-
4.
Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery.
Environ Health Perspect. 2001;109 Suppl 1:69-75. doi:10.1289/ehp.01109s169.
-
5.
Rates
SMK.
Plants
as
source
of
drugs.
Toxicon.
2001;39(5):603-613.
doi:10.1016/S0041-
0101(00)00154-9.
-
6.
Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science.
2009;325(5937):161-165. doi:10.1126/science.1168243.
-
7.
Pan SY, Zhou SF, Gao SH, et al. New perspectives on how to discover drugs from herbal medicines:
CAM's
outstanding
contribution
to
modern
therapeutics.
Evid
Based
Complement
Alternat
Med.
2013;2013:627375. doi:10.1155/2013/627375.
-
8.
Booker
A,
Johnston
D,
Heinrich
M.
Value
chains
of
herbal
medicines—research
needs
and
key
challenges
in
the
context
of
ethnopharmacology.
J
Ethnopharmacol.
2012;140(3):624-633.
doi:10.1016/j.jep.2012.01.039.
-
9.
Chavda
VP,
Vihol
D,
Mehta
B,
et
al.
Phytochemical-loaded
liposomes
for
anticancer
therapy:
an
updated review. Nanomedicine (Lond). 2022;17(8):547-568. doi:10.2217/nnm-2021-0463.
-
10.
Singh M, Devi S, Rana VS, et al. Delivery of phytochemicals by liposome cargos: recent progress,
challenges,
and
opportunities.
J
Microencapsul.
2019;36(3):215-235.
doi:10.1080/02652048.2019.1617361.
-
11.
Applications
of
Nanocarriers
as
Drug
Delivery
Vehicles
for
Active
Phytoconstituents.
Curr
Pharm
Des. 2020. doi:10.2174/1381612826666200610111013.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 37
-
12.
Chauhan
D,
Yadav
PK,
Sultana
N,
et
al.
Advancements
in
nanotechnology
for
the
delivery
of
phytochemicals. J Integr Med. 2024;22(4):385-398. doi:10.1016/j.joim.2024.04.005.
-
13.
Barani M, Bilal M, Rahdar A, et al. Phytosomes as innovative delivery systems for phytochemicals: a
comprehensive
review
of
literature.
Int
J
Nanomedicine.
2021;16:6983-7022.
doi:10.2147/IJN.S318416.
-
14.
Li C, Wang Z, Lei H, Zhang D. Recent progress in nanotechnology-based drug carriers for resveratrol
delivery. Drug Deliv. 2023;30(1):2174206. doi:10.1080/10717544.2023.2174206.
-
15.
Santos AC, Pereira I, Pereira-Silva M, et al. Nanocarriers for resveratrol delivery: impact on stability
and solubility concerns. Trends Food Sci Technol. 2019;91:483-497. doi:10.1016/j.tifs.2019.07.048.
-
16.
Homayoonfal
M,
Aminianfar
A,
Asemi
Z,
Yousefi
B.
Application
of
nanoparticles
for
efficient
delivery
of
quercetin
in
cancer
cells.
Curr
Med
Chem.
2024;31(9):1107-1141.
doi:10.2174/0929867330666230301121611.
-
17.
Silvestre F, Santos C, Silva V, et al. Pharmacokinetics of curcumin delivered by nanoparticles and the
relationship
with
antitumor efficacy:
a systematic review. Pharmaceuticals
(Basel). 2023;16(7):943.
doi:10.3390/ph16070943.
-
18.
Li S, Yuan W, Deng G, Wang P, Yang P, Aggarwal BB. Chemical composition and product quality
control
of
turmeric
(Curcuma
longa
L.).
Pharm
Crops.
2011;2:28-54.
doi:10.2174/2210290601102010028.
-
19.
Anand
Anubhav,
Preety
G,
Smriti
O.
Application
of
nanotechnology
for
herbal
medicine
development:
a
review.
Lett
Drug
Des
Discov.
2024;21(8).
doi:10.2174/1570180820666230308105723.
-
20.
Khan
MJ,
Hafeez
A,
Siddiqui
MA.
Nanocarrier
based
delivery
of
berberine:
a
critical
review
on
pharmaceutical
and
preclinical
characteristics
of
the
bioactive.
Curr
Pharm
Biotechnol.
2023;24(11):1449-1464. doi:10.2174/1389201024666230112141330.
-
21.
Chopra H, Bibi S, Singh I, et
al.
Emerging trends in
the delivery of resveratrol by nanostructures:
applications
of
nanotechnology
in
life
sciences.
J
Nanomater.
2022;2022:3083728.
doi:10.1155/2022/3083728.
-
22.
Song
Y,
Zhang
J,
Zhu
L,
Zhang
H,
Wu
G,
Liu
T.
Recent
advances
in
nanodelivery
systems
of
resveratrol
and
their
biomedical
and
food
applications:
a
review.
Food
Funct.
2024;15:8629-8643.
doi:10.1039/D3FO03892K.
-
23.
FDA.
Considering
whether
an
FDA-regulated
product
involves
the
application
of
nanotechnology:
guidance for industry. Silver Spring (MD): US Food and Drug Administration; 2014.
-
24.
US
Food
and
Drug
Administration.
Drug
products,
including
biological
products,
that
hold
nanomaterials: guidance for industry. Silver Spring (MD): FDA; 2022.
-
25.
European
Medicines
Agency.
Reflection
paper
on
nanotechnology-based
medicinal
products
for
human use. London: EMA; 2006.
-
26.
European
Medicines
Agency.
Reflection
paper
on
the
data
requirements
for
intravenous
liposomal
products developed with reference to an innovator liposomal product. London: EMA; 2013.
-
27.
International Organization for Standardization. ISO/TR 13014:2012 Nanotechnologies—guidance on
physico-chemical
characterization
of
engineered
nanoscale
materials
for
toxicologic
assessment.
Geneva: ISO; 2012.
-
28.
International Organization for Standardization. ISO 21363:2020 Nanotechnologies—measurements of
particle size and shape distributions by transmission electron microscopy. Geneva: ISO; 2020.
-
29.
International Organization for Standardization. ISO 22412:2017 Particle size analysis—dynamic light
scattering (DLS). Geneva: ISO; 2017.
-
30.
International
Organization
for
Standardization.
ISO
10993-1:2018
Biological
evaluation
of
medical
devices—part 1: evaluation and testing within a risk management process. Geneva: ISO; 2018.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 38
-
31.
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision
nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-
0090-8.
-
32.
Shi
J,
Kantoff
PW,
Wooster
R,
Farokhzad
OC.
Cancer
nanomedicine:
progress,
challenges,
and
opportunities. Nat Rev Cancer. 2017;17(1):20-37. doi:10.1038/nrc.2016.108.
-
33.
Peer
D,
Karp
JM,
Hong
S,
Farokhzad
OC,
Margalit
R,
Langer
R.
Nanocarriers
as
an
emerging
platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760. doi:10.1038/nnano.2007.387.
-
34.
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to
drug delivery. Nat Biotechnol. 2015;33(9):941-951. doi:10.1038/nbt.3330.
-
35.
Anselmo
AC,
Mitragotri
S.
Nanoparticles
in
the
clinic.
Bioeng
Transl
Med.
2016;1(1):10-29.
doi:10.1002/btm2.10003.
-
36.
Anselmo
AC,
Mitragotri
S.
Nanoparticles
in
the
clinic:
an
update.
Bioeng
Transl
Med.
2019;4(3):e10143. doi:10.1002/btm2.10143.
-
37.
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of
FDA-approved
materials
and
clinical
trials
to
date.
Pharm
Res.
2016;33(10):2373-2387.
doi:10.1007/s11095-016-195 nanoparticle.
-
38.
Ventola
CL.
Progress
in
nanomedicine:
approved
and
investigational
nanodrugs.
P
T.
2017;42(12):742-755.
-
39.
Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater.
2016;1:16014. doi:10.1038/natrevmats.2016.14.
-
40.
Danhier
F,
Feron
O,
Préat
V.
To
exploit
the
tumor
microenvironment:
passive
and
active
tumor
targeting
of
nanocarriers
for
anti-cancer
drug
delivery.
J
Control
Release.
2010;148(2):135-146.
doi:10.1016/j.jconrel.2010.08.027.
-
41.
Jain
RK,
Stylianopoulos
T.
Delivering
nanomedicine
to
solid
tumors.
Nat
Rev
Clin
Oncol.
2010;7(11):653-664. doi:10.1038/nrclinonc.2010.139.
-
42.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in
macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284. doi:10.1016/S0168-
3659(99)00248-5.
-
43.
Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress, and challenges towards targeted delivery
of cancer therapeutics. Nat Commun. 2018;9:1410. doi:10.1038/s41467-018-03705-y.
-
44.
Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems.
Pharmacol Rep. 2012;64(5):1020-1037. doi:10.1016/S1734-1140(12)70901-5.
-
45.
Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv
Drug Deliv Rev. 2013;65(1):36-48. doi:10.1016/j.addr.2012.09.037.
-
46.
Sercombe
L,
Veerati
T,
Moheimani
F,
Wu
SY,
Sood
AK,
Hua
S.
Advances
and
challenges
of
liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.00286.
-
47.
Akbarzadeh
A,
Rezaei-Sadabady
R,
Davaran
S,
et
al.
Liposome:
classification,
preparation,
and
applications. Nanoscale Res Lett. 2013;8:102. doi:10.1186/1556-276X-8-102.
-
48.
Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975-999.
doi:10.2147/IJN.S68861.
-
49.
Immordino
ML,
Dosio
F,
Cattel
L.
Stealth
liposomes:
review
of
the
basic
science,
rationale,
and
clinical applications, existing, and potential. Int J Nanomedicine. 2006;1(3):297-315.
-
50.
Bulbake
U,
Doppalapudi
S,
Kommineni
N,
Khan
W.
Liposomal
formulations
in
clinical
use:
an
updated review. Pharmaceutics. 2017;9(2):12. doi:10.3390/pharmaceutics9020012.
-
51.
Edwards
K,
Baeumner
A.
Liposomes
in
analyses.
Talanta.
2006;68(5):1432-1441.
doi:10.1016/j.talanta.2005.08.041.
-
52.
Riaz M. Liposomes preparation methods. Pak J Pharm Sci. 1996;9(1):65-77.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 39
-
53.
Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol.
1995;13(12):527-537. doi:10.1016/S0167-7799(00)89017-4.
-
54.
Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen
phospholipids. J Mol Biol. 1965;13(1):238-252. doi:10.1016/S0022-2836(65)80093-6.
-
55.
New RRC, editor. Liposomes: a practical approach. Oxford: IRL Press; 1990.
-
56.
Risselada HJ, Marrink SJ. The molecular face of lipids. Nat Rev Mol Cell Biol. 2009;10(10):739-750.
doi:10.1038/nrm2745.
-
57.
Gregoriadis G. Liposome technology. 3rd ed. Boca Raton: CRC Press; 2006.
-
58.
Singh A, Neupane YR, Panda BP, Kohli K. Lipid-based nanocarriers for drug delivery: a review. J
Drug Deliv Sci Technol. 2020;56:101549. doi:10.1016/j.jddst.2020.101549.
-
59.
Barani
M,
Sangiovanni
E,
Angarano
M,
et
al.
Phytosomes
as
innovative
delivery
systems
for
phytochemicals:
a
comprehensive
review
of
literature.
Int
J
Nanomedicine.
2021;16:6983-7022.
doi:10.2147/IJN.S318416.
-
60.
Bombardelli
E,
Curri
SB,
Della
Loggia
R,
Del
NP,
Tubaro
A,
Gariboldi
P.
Complexes
between
phospholipids and vegetal derivatives of biological interest. Fitoterapia. 1989;60:1-9.
-
61.
Semalty
A,
Semalty
M,
Rawat
MSM,
Franceschi
F.
Supramolecular
phospholipids-polyphenolics
interactions:
the
phytosome
strategy
to
improve
the
bioavailability
of
phytochemicals.
Fitoterapia.
2010;81(5):306-314. doi:10.1016/j.fitote.2009.11.001.
-
62.
Franceschi F, Giori A, Dall'Acqua S, et al. Phytosome: an unfamiliar approach for bioavailability and
pharmacokinetic studies of silymarin. Fitoterapia. 2009;80(7):421-427.
-
63.
Marena C, Lampertico M. Preliminary clinical development of silipide: a new complex of silybin in
toxic liver disorders. Planta Med. 1991;57(2):A124-A125.
-
64.
Bombardelli E, Spelta M. Phospholipid-polyphenol complexes: a new concept in skin care ingredients.
Cosm Toil. 1991;106:69-76.
-
65.
Singh RP, Gangadharappa HV, Mruthunjaya K. Phytosome complexation: a critical review. J Drug
Deliv Sci Technol. 2016;35:201-210. doi:10.1016/j.jddst.2016.06.005.
-
66.
Yanyu X, Yunmei S, Zhipeng C, Qineng P. The preparation of silybin-phospholipid complex and the
study
on
its
pharmacokinetics
in
rats.
Int
J
Pharm.
2006;307(1):77-82.
doi:10.1016/j.ijpharm.2005.10.001.
-
67.
Freag
MS,
Elnaggar
YSR,
Abdallah
OY.
Lyophilized
phytosomal
nanocarriers
as
platforms
for
enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomedicine. 2013;8:2385-
2397. doi:10.2147/IJN.S44851.
-
68.
Manach
C,
Scalbert
A,
Morand
C,
Rémésy
C,
Jiménez
L.
Polyphenols:
food
sources
and
bioavailability. Am J Clin Nutr. 2004;79(5):727-747. doi:10.1093/ajcn/79.5.727.
-
69.
Scalbert
A,
Williamson
G.
Dietary
intake
and
bioavailability
of
polyphenols.
J
Nutr.
2000;130(8S
Suppl):2073S-2085S. doi:10.1093/jn/130.8.2073S.
-
70.
Del
Rio
D,
Rodriguez-Mateos
A,
Spencer
JPE,
Tognolini
M,
Borges
G,
Crozier
A.
Dietary
(poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against
chronic diseases. Antioxid Redox Signal. 2013;18(14):1818-1892. doi:10.1089/ars.2012.4581.
-
71.
Crozier
A,
Jaganath
IB,
Clifford
MN.
Dietary
phenolics:
chemistry,
bioavailability,
and
effects
on
health. Nat Prod Rep. 2009;26(8):1001-1043. doi:10.1039/B802662A.
-
72.
Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93
intervention studies. Am J Clin Nutr. 2005;81(1 Suppl):243S-255S. doi:10.1093/ajcn/81.1.243S.
-
73.
Holst
B,
Williamson
G.
Nutrients,
and
phytochemicals:
from
bioavailability
to
bioefficacy
beyond
antioxidants. Curr Opin Biotechnol. 2008;19(2):73-82. doi:10.1016/j.copbio.2008.03.003.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 40
-
74.
Rein
MJ,
Renouf
M,
Cruz-Hernandez
C,
Actis-Goretta
L,
Thakkar
SK,
da
Silva
Pinto
M.
Bioavailability
of
bioactive
food
compounds:
a
challenging
journey
to
bioefficacy.
Br
J
Clin
Pharmacol. 2013;75(3):588-602. doi:10.1111/j.1365-2125.2012.04425.x.
-
75.
Parada J, Aguilera JM. Food microstructure affects the bioavailability of several nutrients. J Food Sci.
2007;72(2):R21-R32. doi:10.1111/j.1750-3841.2007.00274.x.
-
76.
McClements
DJ.
Enhancing
the
bioavailability
of
hydrophobic
nutraceuticals:
the
role
of
food
structure and colloidal delivery systems. Food Funct. 2010;1(1):32-47. doi:10.1039/C0FO0016B.
-
77.
McClements
DJ,
Li
F,
Xiao
H.
The
nutraceutical
bioavailability
classification
scheme:
classifying
nutraceuticals
according
to
factors
limiting
their
oral
bioavailability.
Annu
Rev
Food
Sci
Technol.
2015;6:299-327. doi:10.1146/annurev-food-032814-014043.
-
78.
McClements
DJ.
Nanoemulsions
versus
microemulsions:
terminology,
differences,
and
similarities.
Soft Matter. 2012;8:1719-1729. doi:10.1039/C2SM06903B.
-
79.
McClements DJ, Rao J. Food-grade nanoemulsions: formulation, fabrication, properties, performance,
biological
fate,
and
potential
toxicity.
Crit
Rev
Food
Sci
Nutr.
2011;51(4):285-330.
doi:10.1080/10408398.2011.559558.
-
80.
Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: formation, properties, and applications. Soft
Matter. 2016;12:2826-2841. doi:10.1039/C5SM02958A.
-
81.
Solans
C,
Izquierdo
P,
Nolla
J,
Azemar
N,
Garcia-Celma
MJ.
Nano-emulsions.
Curr
Opin
Colloid
Interface Sci. 2005;10(3-4):102-110. doi:10.1016/j.cocis.2005.06.004.
-
82.
Tadros T, Izquierdo P, Esquena J, Solans C. Formation, and stability of nano-emulsions. Adv Colloid
Interface Sci. 2004;108-109:303-318. doi:10.1016/j.cis.2003.10.023.
-
83.
Jaiswal
M,
Dudhe
R,
Sharma
PK.
Nanoemulsion:
an
advanced
mode
of
drug
delivery
system.
3
Biotech. 2015;5(2):123-127. doi:10.1007/s13205-014-0214-0.
-
84.
Anton
N,
Benoit
JP,
Saulnier
P.
Design,
and
production
of
nanoparticles
formulated
from
nano-
emulsion
templates—a
review.
J
Control
Release.
2008;128(3):185-199.
doi:10.1016/j.jconrel.2008.02.007.
-
85.
Rao J, McClements DJ. Food-grade microemulsions and nanoemulsions: role of oil phase composition
on
formation
and
stability.
Food
Hydrocoll.
2011;25(6):1413-1423.
doi:10.1016/j.foodhyd.2011.02.014.
-
86.
Date
AA,
Desai
N,á
Nagarsenker
M.
Parenteral
microemulsions:
an
overview.
Int
J
Pharm.
2010;355(1-2):19-30.
-
87.
Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization, and applications. Adv
Drug Deliv Rev. 2001;47(2-3):165-196. doi:10.1016/S0169-409X(01)00105-3.
-
88.
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review
of
the
state
of
the
art.
Eur
J
Pharm
Biopharm.
2000;50(1):161-177.
doi:10.1016/S0939-
6411(00)00087-4.
-
89.
Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of
drugs. Int J Pharm. 2002;242(1-2):121-128. doi:10.1016/S0378-5173(02)00180-1.
-
90.
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical
dermal products. Int J Pharm. 2009;366(1-2):170-184. doi:10.1016/j.ijpharm.2008.10.003.
-
91.
Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and
future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
-
92.
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers:
structure,
preparation,
and
application.
Adv
Pharm
Bull.
2015;5(3):305-313.
doi:10.15171/apb.2015.043.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 41
-
93.
Severino
P,
Andreani
T,
Macedo
AS,
et
al.
Current
state-of-art
and
current
trends
on
lipid
nanoparticles
(SLN
and
NLC)
for
oral
drug
delivery.
J
Drug
Deliv.
2012;2012:750891.
doi:10.1155/2012/750891.
-
94.
Fangueiro JF, Silva AM, Garcia ML, Souto EB. Advanced formulations for topical delivery of anti-
inflammatory drugs. Expert Opin Drug Deliv. 2014;11(10):1609-1622.
-
95.
Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug
delivery:
I.
Production,
characterization,
and
sterilization.
J
Control
Release.
1994;30(1):83-96.
doi:10.1016/0168-3659(94)90047-7.
-
96.
Radtke M, Müller RH. Nanostructured lipid drug carriers. New Drugs. 2001;2:48-52.
-
97.
Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for
topical use: drug release properties. J Control Release. 2000;66(2-3):115-126.
-
98.
Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid
lipid nanoparticle dispersions. Int J Pharm. 1998;168(2):221-229.
-
99.
Fattal
E,
Barratt
G.
Nanotechnologies,
and
controlled
release
systems
for
the
delivery
of
antisense
oligonucleotides and siRNA. Adv Drug Deliv Rev. 2009;61(9):836-846.
-
100.
Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers, and polymeric
nanoparticles:
mechanisms
of
controlling
drug
release.
Chem
Rev.
2016;116(4):2602-2663.
doi:10.1021/acs.chemrev.5b00346.
-
101.
Makadia
HK,
Siegel
SJ.
Poly
lactic-co-glycolic
acid
(PLGA)
as
biodegradable
controlled
drug
delivery carrier. Polymers (Basel). 2011;3(3):1377-1397. doi:10.3390/polym3031377.
-
102.
Danhier
F,
Ansorena
E,
Silva
JM,
Coco
R,
Le
Breton
A,
Préat
V.
PLGA-based
nanoparticles:
an
overview
of
biomedical
applications.
J
Control
Release.
2012;161(2):505-522.
doi:10.1016/j.jconrel.2012.01.043.
-
103.
Jain
RA.
The
manufacturing
techniques
of
various
drug
loaded
biodegradable
poly(lactide-co-
glycolide)
(PLGA)
devices.
Biomaterials.
2000;21(23):2475-2490.
doi:10.1016/S0142-
9612(00)00115-0.
-
104.
Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282(1-2):1-
18. doi:10.1016/j.ijpharm.2004.04.013.
-
105.
Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles.
Pharm Res. 2009;26(5):1025-1058. doi:10.1007/s11095-008-9800-3.
-
106.
Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-
loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8-21. doi:10.1016/j.nano.2005.12.003.
-
107.
Soppimath
KS,
Aminabhavi
TM,
Kulkarni
AR,
Rudzinski
WE.
Biodegradable
polymeric
nanoparticles
as
drug
delivery
devices.
J
Control
Release.
2001;70(1-2):1-20.
doi:10.1016/S0168-
3659(00)00339-4.
-
108.
Li Y, MacDowell N, Langer R, et al. Polymer nanoparticles for drug delivery. Nat Rev Mater. 2021.
-
109.
Kamaly
N,
Xiao
Z,
Valencia
PM,
Radovic-Moreno
AF,
Farokhzad
OC.
Targeted
polymeric
therapeutic
nanoparticles:
design,
development,
and
clinical
translation.
Chem
Soc
Rev.
2012;41(7):2971-3010. doi:10.1039/C2CS15344K.
-
110.
Elsabahy
M,
Wooley
KL.
Design
of
polymeric
nanoparticles
for
biomedical
delivery
applications.
Chem Soc Rev. 2012;41(7):2545-2561. doi:10.1039/C1CS15219C.
-
111.
Riley T, Govender T, Stolnik S, Xiong CD, Garnett MC, Illum L, Davis SS. Colloidal stability and
drug incorporation aspects of micellar systems. Int J Pharm. 1999;191(2):147-156.
-
112.
Jones MC, Leroux JC. Polymeric micelles—a new generation of colloidal drug carriers. Eur J Pharm
Biopharm. 1999;48(2):101-111. doi:10.1016/S0939-6411(99)00039-9.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 42
-
113.
Blanazs A, Armes SP, Ryan AJ. Self-assembled block copolymer aggregates: from micelles to vesicles
and
their
biological
applications.
Macromol
Rapid
Commun.
2009;30(4-5):267-277.
doi:10.1002/marc.200800713.
-
114.
Cabral
H,
Kataoka
K.
Progress
of
drug-loaded
polymeric
micelles
into
clinical
studies.
J
Control
Release. 2014;190:465-476. doi:10.1016/j.jconrel.2014.06.042.
-
115.
Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug
delivery platform. ACS Nano. 2008;2(8):1696-1702. doi:10.1021/nn800275r.
-
116.
Hu
CMJ,
Zhang
L.
Nanoparticle-based
combination
therapy
toward
overcoming
drug
resistance
in
cancer. Biochem Pharmacol. 2012;83(8):1104-1111.
-
117.
Peer
D,
Lieberman
J.
Special
delivery:
targeted
therapy
with
small
RNAs.
Gene
Ther.
2011;18(12):1127-1133. doi:10.1038/gt.2011.56.
-
118.
Yoo
JW,
Doshi
N,
Mitragotri
S.
Adaptive
micro
and
nanoparticles:
temporal
control
over
carrier
properties to facilitate drug delivery. Adv Drug Deliv Rev. 2011;63(14-15):1247-1256.
-
119.
De
Jong
WH,
Borm
PJA.
Drug
delivery
and
nanoparticles:
applications
and
hazards.
Int
J
Nanomedicine. 2008;3(2):133-149.
-
120.
Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio
interface. Nat Mater. 2009;8(7):543-557. doi:10.1038/nmat2442.
-
121.
Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity
of nanosized materials. Nat Nanotechnol. 2012;7(12):779-786. doi:10.1038/nnano.2012.207.
-
122.
Tenzer
S,
Docter
D,
Kuharev
J,
et
al.
Rapid
formation
of
plasma
protein
corona
critically
affects
nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772-781. doi:10.1038/nnano.2013.181.
-
123.
Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting
capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137-143.
doi:10.1038/nnano.2012.237.
-
124.
Fadeel
B,
Garcia-Bennett
AE.
Better
safe
than
sorry:
understanding
the
toxicological
properties
of
inorganic
nanoparticles
manufactured
for
biomedical
applications.
Adv
Drug
Deliv
Rev.
2010;62(3):362-374. doi:10.1016/j.addr.2009.11.008.
-
125.
Nel
A,
Xia
T,
Mädler
L,
Li
N.
Toxic
potential
of
materials
at
the
nanolevel.
Science.
2006;311(5761):622-627. doi:10.1126/science.1114397.
-
126.
Donaldson
K,
Stone
V,
Tran
CL,
Kreyling
W,
Borm
PJA.
Nanotoxicology.
Occup
Environ
Med.
2004;61(9):727-728. doi:10.1136/oem.2004.013243.
-
127.
Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity
of nanosized materials. Nat Nanotechnol. 2012;7(12):779-786. doi:10.1038/nnano.2012.207.
-
128.
Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the in vivo and
in
vitro
toxicity
of
silver
and
gold
particulates.
Crit
Rev
Toxicol.
2010;40(4):328-346.
doi:10.3109/10408440903453074.
-
129.
Khlebtsov N, Dykman L. Biodistribution, and toxicity of engineered gold nanoparticles: a review of in
vitro and in vivo studies. Chem Soc Rev. 2011;40(3):1647-1671. doi:10.1039/C0CS00018C.
-
130.
European
Commission.
Commission
recommendation
of
10
June
2022
on
the
definition
of
nanomaterial. Off J Eur Union. 2022;C229:1-5.
-
131.
International
Council
for
Harmonisation.
ICH
Q8(R2):
Pharmaceutical
development.
Geneva:
ICH;
2009.
-
132.
International Council for Harmonisation. ICH Q9(R1): Quality risk management. Geneva: ICH; 2023.
-
133.
International
Council
for
Harmonisation.
ICH
Q10:
Pharmaceutical
quality
system.
Geneva:
ICH;
2008.
-
134.
International Council for Harmonisation. ICH Q1A(R2): Stability testing of new drug substances and
products. Geneva: ICH; 2003.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 43
-
135.
International Council for Harmonisation. ICH M3(R2): Nonclinical safety studies for the conduct of
human clinical trials and marketing authorization for pharmaceuticals. Geneva: ICH; 2009.
-
136.
International
Council
for
Harmonisation.
ICH
S9:
Nonclinical
evaluation
for
anticancer
pharmaceuticals. Geneva: ICH; 2009.
-
137.
International Council for Harmonisation. ICH E6(R2): Good clinical practice. Geneva: ICH; 2016.
-
138.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for
reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
-
139.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised
trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
-
140.
Hooijmans
CR,
Rovers
MM,
de
Vries
RBM,
Leenaars
M,
Ritskes-Hoitinga
M,
Langendam
MW.
SYRCLE's
risk
of
bias
tool
for
animal
studies.
BMC
Med
Res
Methodol.
2014;14:43.
doi:10.1186/1471-2288-14-43.
-
141.
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that
include
randomised
or
non-randomised
studies
of
healthcare
interventions,
or
both.
BMJ.
2017;358:j4008. doi:10.1136/bmj.j4008.
-
142.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence
and
strength
of
recommendations.
BMJ.
2008;336(7650):924-926.
doi:10.1136/bmj.39489.470347.AD.
How to cite this article:
Abhishek Tripathi, Harroshandeep Kaur Phull,Hepatotoxicity and Nephrotoxicity of Widely Used Medicinal
Herbs: A Critical Appraisal of Safety Evidence Against the Assumption That “Natural” Means Safe. (2026).
International Journal of
Pharmaceutical Research and Medicinal Plants
,
2
(5),27-44.
https://doi.org/10.61280/89qdmp44
Published by:
Informative Journals
Jadoun Science Publishing Group India
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 44